Loading
A phase 3 trial of Dostarlimab in head and neck squamous cell carcinoma, run by GlaxoSmithKline, now recruiting.
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma is a phase 3 interventional study registered as NCT06256588 by GlaxoSmithKline, with 864 participants planned, started 2024-03-21 and due to reach its primary completion in 2028-06-30. Interventions recorded: Dostarlimab and Placebo.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares A funded programme of organ-preservation trials to avoid radical surgery, Dostarlimab, GSK, Head and neck squamous cell carcinoma and the tag pipeline.
Shares A funded programme of organ-preservation trials to avoid radical surgery, Dostarlimab, GSK, Immune checkpoint inhibitors and the tag pipeline.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors and the tag pipeline.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors and the tag pipeline.
Shares Dostarlimab, GSK, Immune checkpoint inhibitors and the tag pipeline.
Shares Dostarlimab, GSK and the tag pipeline.
Shares Dostarlimab, GSK and the tag pipeline.
Shares A funded programme of organ-preservation trials to avoid radical surgery, Dostarlimab, GSK, Immune checkpoint inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/